Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Investor Presentation (March 2020)
19 slides from Little Green Pharma's investor presentation, Mar 16, 2020
Slide 1: Investor Presentation March 2020
For personal use only Investor Presentation March 2020
Slide 2: Disclaimer
Disclaimer NOT AN OFFER OF SECURITIES For personal use only This document has been independently prepared by Little Green Pharma Ltd ACN 615 586 215 (LGP) and is provided for informational purposes only. This document does not constitute or contain an offer, invitation, solicitation or recommendatio
Slide 3: Company Overview
Company Overview Little Green Pharma is a leading vertically integrated medicinal cannabis business 1 with existing sales and a clear pathway to increasing margins & driving significant revenue growth in domestic & European markets For personal use only Vertically integrated Expansion of cultivation
Slide 4: Board & Key Management
Board & Key Management Commercial and execution-focused Board and Management Team For personal use only Fleta Solomon, Managing Director Angus Caithness, Executive Director • Grown LGP from start up phase to an industry leading pharmaceutical • Experience in corporate finance & consulting both local
Slide 5: H1FY2020 Financial & Operational Highlights
H1FY2020 Financial & Operational Highlights Significant operational momentum For personal use only Revenue (H1FY20) Gross Margin (H1FY20) Biological Assets (H1FY20) Up 188% to $716,000 54%1, up from 41% Up 30% to $667,570 for 6 months vs. 12 months to FY19 vs. FY19 vs. end FY19 Patients (to 29 Feb 2
Slide 6: Progress Since Prospectus Lodgement
Progress Since Prospectus Lodgement LGP has made considerable commercial progress since October 2019 For personal use only Granted expansion to Medicinal 3-year sales agreement signed with 5-year sales agreement signed with Cannabis Licence and new DEMECAN for 1,000kg of dried flower Astral Health t
Slide 7: Track Record of Growing Patient Access
Track Record of Growing Patient Access Strong growth in sales and patients using LGP products in Australia For personal use only 9,000 2,900+ Patients using LGP’s 3,000 products in Australia 8,000 2,500 7,000 Unique Paitents Using LGP Products (#) 6,000 2,000 LGP Bottles Sold (#) 5,000 1,500 4,000 3
Slide 8: LGP Business Model
LGP Business Model Integrated model captures the medicinal cannabis value chain For personal use only Business Model Overview Cultivation & Production Manufacturing Branding and R&D Distribution Education Programs • Capacity to cultivate a • Exclusive agreement1 with • Strong in-market brand, • 18-m
Slide 9: Cultivation and Production
Cultivation and Production Facility expansion on time and on budget to be completed in 1QCY2020 For personal use only • Indoor hydroponic facility located in the southwest of WA • ODC & GACP-compliant – suitable for medicinal cannabis cultivation according to Australian and German requirements Curre
Slide 10: Manufacturing
Manufacturing Exclusively partnered with a TGA-GMP licensed pharmaceutical manufacturer For personal use only • Exclusive agreement1 with Western Australia’s only fully licenced Manufacturing capability for multiple delivery technologies TGA-GMP medicinal cannabis manufacturing facility Derma Skinca
Slide 11: Branded Product Range
Branded Product Range First mover advantage with strong in-market brand For personal use only Current Product Range Product Development Classic Range Atomised Rapid Injection for Solvent Extraction (ARISE) • LGP Classic products are registered with the ARTG – ready for • LGP has been granted an excl
Slide 12: New Product – LGP Classic CBD
New Product – LGP Classic CBD 50 Major milestone reached as LGP releases CBD only product For personal use only LGP is pleased to announce the launch of LGP Classic CBD 50 • LGP’s first CBD only product provides access to new market seeking CBD dominant products o Targets large addressable market –
Slide 13: Product Development
Product Development Expanding the range of delivery methods to drive margin expansion For personal use only Further Delivery Systems • LGP’s manufacturing partner has the capability to adapt to a variety of delivery methods (e.g. suppositories, capsules, or sprays) • LGP is engaged with a research o
Slide 14: Distribution & Export
Distribution & Export LGP has penetrated key foreign jurisdictions and is expanding rapidly For personal use only Australia • Already distributing to over 2,900 SAS-B and Authorised Prescriber patients, via local and national distributors, and pharmacies • LGP is driving patient access through marke
Slide 15: European Distribution Strategy
European Distribution Strategy Clear and defined strategy to capitalise on the market opportunity in Germany and the UK For personal use only 1 2 3 4 Compliance with legal Distribution infrastructure Leverage production Export opportunities framework experience and first mover advantage ✓ Single Con
Slide 16: Education Programmes
Education Programmes Key driver of LGP’s educational mission and distribution strategy For personal use only • Educating all healthcare practitioners and medicinal cannabis supply chain participants is a key component of LGP’s mission and distribution strategy 210+ healthcare practitioners have Educ
Slide 17: Growth Strategy Summary
Growth Strategy Summary LGP will pursue a progressive growth strategy as the market develops and grows For personal use only Existing growth initiatives Immediately available opportunities Longer-term opportunities Complete expansion of the cultivation facility Establish European hub and in-house to
Slide 18: News Flow
News Flow Significant news flow as LGP executes growth strategy For personal use only Completion of cultivation facility expansion First crop planting at expanded facility First product delivered to Astral Health in the UK Further expansion of product line with new LGP Classic CBD products Update on
Slide 19: For personal use only
For personal use only
Little Green Pharma — Investor Presentation (March 2020) on 6ix